These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 19706063)
21. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. Després JP; Golay A; Sjöström L; N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982 [TBL] [Abstract][Full Text] [Related]
22. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Patel PN; Pathak R Am J Health Syst Pharm; 2007 Mar; 64(5):481-9. PubMed ID: 17322160 [TBL] [Abstract][Full Text] [Related]
23. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists? Di Marzo V Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695 [No Abstract] [Full Text] [Related]
24. Panel advises against rimonabant approval. Traynor K Am J Health Syst Pharm; 2007 Jul; 64(14):1460-1. PubMed ID: 17617490 [No Abstract] [Full Text] [Related]
33. Rimonabant and progression of atherosclerosis in obese persons. Dora JM; Scheffel RS JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538 [No Abstract] [Full Text] [Related]
34. Effect of rimonabant on weight reduction and cardiovascular risk. Hirschel B Lancet; 2005 Jul 30-Aug 5; 366(9483):369; author reply 369-70. PubMed ID: 16054934 [No Abstract] [Full Text] [Related]
35. Withdrawal of Rimonabant--walking the tightrope of 21st century pharmaceutical regulation? Taylor D Curr Drug Saf; 2009 Jan; 4(1):2-4. PubMed ID: 19256104 [No Abstract] [Full Text] [Related]
36. [Rimonabant--a panacea for patients with metabolic syndrome?]. Broncel M; Koziróg M Pol Arch Med Wewn; 2006 Aug; 116(2):787-93. PubMed ID: 17424926 [No Abstract] [Full Text] [Related]
37. Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer. Wright KL; Robertson DA; Moyer MP; Ward SG Int J Cancer; 2008 Apr; 122(8):1920-1. PubMed ID: 18076045 [No Abstract] [Full Text] [Related]
38. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]. Ducobu J; Sternon J J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510 [TBL] [Abstract][Full Text] [Related]
39. [Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects]. Wettermark B; Raaschou P; Forslund T; Hjemdahl P Lakartidningen; 2007 Dec; 104(51-52):3879-81. PubMed ID: 18232530 [No Abstract] [Full Text] [Related]
40. Effect of rimonabant on weight and cardiometabolic risk factors. Gadde KM JAMA; 2006 Aug; 296(6):649-50; author reply 650-1. PubMed ID: 16896103 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]